The trial will explore the effects of higher doses of ACD856, building on the drug’s established safety profile.

Emcure Pharmaceuticals on Thursday reported a 30.3% year-on-year ... The company’s EBITDA rose 23.2% YoY to Rs 362 crore crore, while the EBITDA margin rose 80 basis points YoY to 18.4%. The EBITDA ...

Emcure Pharma on February 6 reported a net profit of Rs 153.72 crore for the third quarter of the current financial year. This marks a rise of over 35 percent from the Rs 113.45 crore net profit ...

Emcure Pharmaceuticals Ltd reported a 30.3% year-on-year (YoY) increase in net profit, which rose to ₹156 crore in the third quarter of FY25, up from ₹119.7 crore in the same period last year. The ...

The total estimated value of the contract is seen at Rs 247.55 crore. Emcure Pharmaceuticals: The drugmaker company has received an order confirming demand for tax, interest, and penalty from the ...

(MENAFN- Adfactors PR) Bengaluru, January 31, 2025: Cricket legend M.S. Dhoni and Emcure Pharma’s Whole-Time Director Namita Thapar have come together in a powerful conversation to highlight the ...

HOOKIPA Pharma (HOOK) announced that enrollment is complete in the Phase 1b clinical trial evaluating HB-500 for the treatment of HIV, with 30 participants enrolled across five sites in the United ...

HOOKIPA Pharma Inc. has announced the completion of participant enrollment in a Phase 1b clinical trial for HB-500, a next-generation therapeutic vaccine aimed at treating HIV. The trial ...

"Renalys Pharma") announced today that it has completed patient enrollment for its registrational Phase III clinical trial of sparsentan for the treatment of IgA nephropathy in Japan. In April ...

aTyr Pharma ... 2 to resolve inflammation without immune suppression and potentially prevent the progression of fibrosis. aTyr is currently investigating efzofitimod in the global Phase 3 EFZO ...

January 28, 2025 I Herantis Pharma Plc (“Herantis”), a company developing disease-modifying therapies for Parkinson’s disease, is pleased to announce an update of the ongoing Phase 1b clinical trial ...